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We report a methodology for labeling the GABAc receptor on the surface membrane of intact cells. This work builds upon
our earlier work with serotonin-conjugated quantum dots and our studies with PEGylated quantum dots to reduce nonspeciﬁc
binding. In the current approach, a PEGylated derivative of muscimol was synthesized and attached via an amide linkage to
quantum dots coated in an amphiphilic polymer derivative of a modiﬁed polyacrylamide. These conjugates were used to image
GABAC receptors heterologously expressed in Xenopus laevis oocytes.
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1. INTRODUCTION
Quantum dots (qdots) are nanometer-sized semiconductor
crystals that have unique physical properties that diﬀer from
bulk material. The ﬂuorescent properties of qdots have been
widely described, and numerous applications based upon
these ﬂuorescent properties have been reported. In addition,
previous studies have reported the properties of many
varieties of qdots [1–8]. Of these, the most widely studied
are cadmium selenide/zinc sulﬁde core-shell nanocrystals.
These consist of a semiconductor core of cadmium selenide
encapsulated in a multilayer shell of zinc sulﬁde doped with
cadmium[9].Theshellpassivatesthesurfaceofthecore,and
thebandgapiswiderthanthatofthecore,enablingquantum
conﬁnement of an electron-hole pair generated in the core
after photoexcitation. Ultimately, the electron hole pair
recombines, resulting in a ﬂuorescent emission of a lower-
energyphotoninthevisibleregionofthespectrum[10].The
energy of the emitted photon is determined by the size of
the quantum conﬁnement (or the size of the qdot). Smaller
qdots emit blue light and larger ones emit red light. Qdots
have several advantages over conventional ﬂuorescent dyes;
these include increased photostability, increased brightness,
quantum yields in excess of 80–90% [1, 9, 11], and a narrow
emission spectrum (less than 30nm full width at half-
maximum in commercial products) [12–15]. Furthermore,
their multivalent surfaces enable the attachment of more
than one type of ligand or multiple copies of a ligand to a
single qdot.
Since their introduction into biology as imaging agents
in 1998 [16, 17], qdots have increasingly found applications
as ﬂuorescent probes in biology. To be useful as ﬂuorescent
probes in biological systems, qdots must be soluble in
water and commonly used buﬀers. Additionally, they must
have colloidal stability and low nonspeciﬁc adsorption to
cellular membranes. These properties have been achieved
using a number of techniques, including encapsulation in
micelles[18],silanization [19],encapsulationinamphiphilic
polymers [20, 21], and encapsulation in proteins such as
streptavidin [22]. To further reduce nonspeciﬁc adsorption
to cellular membranes, a number of techniques may be used
to modify the surface chemistry of qdots. For example, we
have recently demonstrated that nonspeciﬁc binding can
be signiﬁcantly reduced by attaching polyethylene glycol
chains (i.e., by PEGylating) qdots coated in an amphiphilic
modiﬁed polyacrylic acid polymer (AMP) [23]. The length
of the PEG chain and the PEG loading were demonstrated to
be important in reducing nonspeciﬁc adsorption to cellular2 Journal of Biomedicine and Biotechnology
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Figure 1:AcomparisonofnonspeciﬁcadsorptionofAMP-coatedqdotstothesurfacesof6diﬀerentcelltypes.Theseexperimentsemployed
AMP-coated qdots that were either unconjugated (upper row) or conjugated to PEG2000 (lower row).
membranes. When PEGs with short (less than 12) repeat
units were conjugated to qdots, a small reduction in nonspe-
ciﬁc adsorption to cellular membranes was observed. This
reduction increased in magnitude when larger PEGs were
used. Figure 1 shows the eﬀects of PEGylation (PEG2000)
on nonspeciﬁc adsorption to 6 diﬀerent cell types. These
cells were treated with a 50nM solution of PEGylated AMP-
coated qdots or a 50nM solution of AMP-coated qdots. A
signiﬁcant reduction in nonspeciﬁc adsorption to cellular
membranes was obtained by the addition of PEG2000. The
nonspeciﬁc adsorption is cell-type speciﬁc, as can be seen
in the relatively low nonspeciﬁc adsorption of AMP-coated
qdots to the surfaces of 3T3 cells compared to the high levels
of nonspeciﬁc adsorption to HEK cells.
In addition to surface modiﬁcation techniques such as
PEGylation, a wide variety of biologically active molecules
have been attached to qdots, including proteins [24–31],
peptides [32–34], DNA [35–43], RNA [44], peptide nucleic
acid (PNA) [45], cytokines [46], viruses [47], and antibodies
[48–54]. The qdots-based imaging applications that have
been reported in the literature are extensive and encompass
a wide variety of imaging applications. Of these, live cell
imaging [51] and whole animal imaging [52]h a v er e c e i v e d
a great deal of interest. In addition to qdots that emit in the
visibleregionoftheelectromagneticspectrum,near-infrared
qdots have been developed that have a cadmium telluride
core instead of a cadmium selenide core. These near-IR dots
have found applications in the clinic as tools for imaging
sentinel lymph nodes during surgery [53].
Our research eﬀorts focus on the central nervous system.
We are interested in using qdots that have been conjugated
with small molecules [55–60], antibodies [61], and peptides
[34] to image receptors and transporters in cell cultures,
oocytes, and, ultimately, neurons. In our early work, we
used qdots to image the serotonin transporter (SERT) using
PEGylated serotonin ligands [62] attached to the surfaces
of qdots via an acid-base interaction (see Figure 2). These
conjugates antagonized the serotonin transporter protein
(SERT) with an IC50 of 115μM in transfected HEK-293 cells.
UsingtheseconjugateswewereabletoimageSERTexpressed
in HEK-293 cells [55].
Numerous biofunctionalization methods for qdots have
been reported in recent years.Qdot preparations that con-
tain an amphiphilic coating on the qdots surface are
commercially available, and a variety of methodologies,
including those involving sulfo-SMCC [63]a n da d a p t o r
proteins [64], have been used to conjugate ligands to
the coated qdot. Our current strategy uses commercially
available qdots that have either an amphiphilic coating
(AMP) on the surface of the dots, or AMP qdots with an
additional coating of streptavidin. PEGylated ligands may
be attached to the surface of these dots using two diﬀerent
methodologies. Either they may be covalently attached
to the AMP coating using 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (EDC) coupling chemistry,
or a biotinylated derivative of the biologically active ligand
may be attached to the surface of streptavidin-coated qdots
via a streptavidin-biotin interaction. Using the PEGylated
ligand approach, we have synthesized a novel qdot conjugate
and tested its binding activity to the GABAC receptor,
a ligand-gated ion channel that is found in retina and
other central nervous system tissue and that is activated
in vivo by γ-aminobutyric acid (GABA). Speciﬁcally, we
have investigated a PEG derivative of muscimol, a known
agonist of both GABAC and GABAA receptors (see Figure 3).
Multiple copies of this ligand have been conjugated to the
surface of AMP-coated qdots and used to image GABAC
receptors expressed in Xenopus laevis oocytes [65].
2. METHODOLOGY
Streptavidin-coatedqdotsandAMP-coatedqdotswithmaxi-
mumemissionsof605and585nmwereobtainedfromInvit-
rogen (Carlsbad, Calif, USA). N-Hydroxy urea, dimethyl
acetylenedicarboxylate, 1,5-diazabicyclo[5.4.0] undec-7-ene
(DBU),boranedimethylsulﬁde,andN-hydroxysuccinimide
(NHS) were obtained from Sigma-Aldrich (St.Louis, Mo,
USA). Triﬂuoroacetic acid (TFA), potassium hydroxide,
and hydrazine monohydrate were obtained from VWR
(West Chester, Pa, USA). All reagents were used with-
out further puriﬁcation. Borate buﬀer was obtained from
PolySciences, Inc. (Warrington, Pa, USA), and Sephadex
G-50 was obtained from Amersham Biosciences (Uppsala,
Sweden). t-Butyloxacarbamate (BOC)-protected N-hydroxy
succinimide-activated PEG3400 ester (BOC-PEG-NHS) was
obtained from Nektar Therapeutics (Huntsville, Ala, USA).Ian D. Tomlinson et al. 3
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Figure 2: Serotonin-coated qdots used to label SERT-expressing cells.
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Figure 3: Muscimol, a GABAC and GABAA receptor agonist.
2.1. Synthesisofthemuscimolligand
Muscimol was synthesized using the method described by
Frey and J¨ ager [66]. This was then coupled to the PEG
linkerviaanaminohexanoylNHSestertogivethePEGylated
muscimol ligand. The ligand was characterized by matrix-
assisted laser desorption/ionization time-of-ﬂight (MALDI-
TOF) mass spectroscopy and conjugated to AMP-coated
qdots via an EDC coupling.
2.1.1. Muscimolsynthesis
Muscimol was synthesized using the synthetic methodol-
ogy shown in Scheme 1. Dimethyl acetylenedicarboxylate
(3.1mL)wasaddeddropwisetoasolutionofN-hydroxyurea
(1.9g, 25mmols) and DBU (4.19g, 28mmols) in methanol
(25mL) at 0◦C. The resulting solution was stirred at 0◦Cf o r
10 minutes, and then evaporated under reduced pressure.
Concentrated hydrochloric acid was added until a pH of
1 was obtained. This solution was extracted with diethyl
ether, dried over magnesium sulfate, ﬁltered, and then evap-
orated. The resulting solid was recrystallized from methylene
chloride to yield 1.1g of methyl 3-hydroxy isoxazole-5-
carboxylate (I) in a 32% yield. This was converted to (II)
by stirring 0.84g of (I) in ammonium hydroxide (3mL)
and methanol (3mL) for 1 hour, followed by recrystal-
lization from ethanol to give 0.75g of 3-hydroxyisoxazole-
5-carboxamide (II) in 88% yield as the ammonium salt.
Muscimol (III) was obtained from 1g of (II) by reduction
with borane dimethyl sulﬁde in tetrahydrofuran (THF) to
give 0.2g of (III) in a 22% yield after puriﬁcation by ion
exchange chromatography.
2.1.2. SynthesisofPEGylatedmuscimolligand
The synthetic route used to synthesize the PEGylated
muscimol ligand is shown in Scheme 2. Initially, the
aminohexanoyl spacer was synthesized by reacting 6-amino
hexanoic acid with tBOC anhydride in methanol to give
6-(tert-butoxycarbonylamino)hexanoic acid (IV) in a
58% yield. This was converted to 2,5-dioxopyrrolidin-1-yl4 Journal of Biomedicine and Biotechnology
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Scheme 1: Synthesis of Muscimol: (i) DBU, (ii) NH3, and (iii) BH3.
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Scheme 2: Synthesis of muscimol ligand: (i) BOC anhydride, (ii) NHS, DCC, (iii) Muscimol, (iv) TFA,(v) BOC-PEG3400-NHS, and (vi)
TFA.
6-(tert-butoxycarbonylamino)hexanoate (V) by reacting
(IV) with NHS in the presence of dicyclo carbodiimide
(DCC). The product was recrystallized from ether/hexanes
resulting in a 38% yield of (V). This was coupled to musci-
mol in pyridine to give tert-butyl 6-((3-hydroxyisoxazol-5-
yl)methylamino)-6-oxahexylcarbamate (VI) in a 54% yield.
The BOC protecting group was removed using TFA to give
6-amino-N-((3-hydroxyisoxazol-5-yl)methyl)hexanamide
(VII) in a 100% yield. This was coupled to tBOC protected
PEG3400 NHS ester to give (VIII) in 100% yield. The BOC
protecting group was removed using TFA to give (IX).
2.1.3. MALDI-TOFmassspectroscopy
Compounds (VIII) and (IX) were characterized by MALDI-
TOF mass spectroscopy (Applied Biosystems Voyager mass
spectrometer equipped with a 337nm nitrogen laser) using
an acceleration voltage of 25kV, and the spectra were
obtained by averaging of 30–64 scans [65]. The samples
were prepared using a saturated matrix stock solution,
consisting of 2,5-dihydroxybenzoic acid and 0.01M sodium
iodide dissolved in methanol. The PEG derivatives (VIII)
and (IX) were prepared (5mM) in methanol. The sample
was added to the matrix by mixing the sample and stock
solutions in a 2 : 5 : 2 ratio of sample to matrix to salt
(v/v). A 1-μL aliquot of each sample solution was placed
on the sample plate. Mass calibration of the instrument
employed a PEG standard, and was prepared using the same
protocol as that employed for the other samples. Analysis of
the resulting spectra indicated that compounds (VIII) and
(IX) were polydisperse. Compound (VIII) exhibited masses
ranging from 3241Da to 4188Da (indicative of muscimol
conjugation to PEGs of diﬀerent lengths), and a primary
peak at 3726Da. The treatment of (VIII) with TFA to yield
compound (IX) resulted in a MALDI-TOF spectrum shift of
100Da (primary peak at 3626Da), consistent with loss of the
BOC protecting group.
2.1.4. Ligandconjugation
The ligand was conjugated to qdots using an EDC coupling
in which 1000 equivalents of ligand were mixed with 750
equivalents of NHS and EDC in borate buﬀer at pH 8.5.
To this was added a solution of AMP-coated qdots (8.4μM).
This mixture was stirred for 1 hour at ambient temperature.
UnboundligandwasremovedbySephadexG-50chromatog-
raphy. The coupling of amino-terminated PEG2000 to AMP-
coated qdots using EDC has been studied in an earlier
publication, and the eﬃciency of coupling has been reported
to be ∼20% when 2000 equivalents of methoxy-terminatedIan D. Tomlinson et al. 5
aminoPEG2000 are reacted with 1 equivalent of AMP-coated
qdots [23]. Since the terminating muscimol of the present
ligand is attached to PEG3400, the coupling eﬃciency is
likely to be similar. On this basis, we estimate the number
of muscimol ligands to be around 150–200 per qdot [65].
The derivatized qdots were characterized by electrophoresis
in 1% agarose gel (see Figure 4). The gel demonstrates that
the muscimol-conjugated qdots (Lane 3), as well as qdots
conjugated with PEG2000 (Lane 4), have a wide distribution
in the number of ligands attached to their surface, as they
streak on the gel more than unconjugated qdots (Lane 2). It
is important to note that mobility in the gel does not depend
merely on mass, but rather on mass-to-charge ratio. Thus,
despite the substantial diﬀerence in mass of the PEG2000
versus the muscimol-terminated PEG3400 ligand, the bands
representing the qdots conjugates that contain (numerous
copies of) these ligands exhibit similar mobilities (Lanes 3
and 4). The present experimental conditions (1% agarose
gel) do not separate protein standards that span a molecular
weight range of 10–250kDa (data not shown).
2.2. Oocyteimaging
The oocytes used in this study were obtained from adult
female X. laevis toads. The oocytes were stored in physio-
logical saline (Ringer solution; 100mM NaCl, 2mM KCl,
2mM CaCl 2,1 m MM g C l 2,1 0 m Mg l u c o s e ,a n d5 m M
HEPES, pH 7.4). Using previously reported procedures, we
expressed GABAC receptors (human ρ1a n dp e r c hρ1B)
in X. laevis oocytes [67, 68]. cRNA (50nL) for each of
the receptor subunits was injected into the oocyte, and
the oocytes were assayed after 18–72-hour incubation in
Ringer solution containing 0.1mg/mL gentamycin at 16–
19
◦C to allow for expression of the GABAC receptors.
Oocyte imaging was carried out in a glass-bottom dish
into which GABAC expressing oocytes and oocytes that
did not express GABAC were placed. These oocytes were
incubated for 5–10 minutes in a drop (∼25μL) of solution
containing either 34nM AMP-coated qdots conjugated to
the muscimol ligand, or 34nM AMP-coated qdots that
lacked conjugated muscimol ligand. The oocytes were then
imaged using a confocal microscope (Leica model DM-
IRE2 with 20x objective) with excitation at 476nm, and
with detection of ﬂuorescence emission over a wavelength
range (580–620nm) that included the qdot emission peak
(605nm). At the beginning of experiments conducted on
a given day, we established microscope settings relevant
to excitation illumination and detection of ﬂuorescence
emission (gain and oﬀset) with use of either a human ρ1
GABAC-expressing or perch ρ1B GABAC-expressing oocyte
incubated with 34nM muscimol-conjugated AMP-coated
qdots.Thesesettingsweremaintainedwithoutchangeforthe
entire day’s measurements [65].
3. RESULTS
3.1. LabelingofGABAC-expressingoocyteswith
muscimol-conjugatedqdots
Figure 5 shows the binding of muscimol-conjugated AMP-
coatedqdotsandunconjugatedAMP-coatedqdotstooocytes
10kb
3kb
1kb
0.5kb
12 3 4
Figure 4: Agarose gel electrophoresis of qdots conjugates (1%
agarose gel; Tris-acetate-EDTA buﬀer containing ethidium bromide
for DNA visualization; 80V potential diﬀerence). A 1-kb DNA
ladder (Lane 1; New England Biolabs, Ipswich, Mass, USA), with
DNA fragments ranging from 0.5–10 kilobases (kb) as indicated,
was utilized to illustrate relative electrophoretic mobility of the
qdot conjugates. Unconjugated AMP-coated qdots (Lane 2) have an
increased mobility by comparison with both muscimol-conjugated
qdots (Lane 3) and qdots conjugated with methoxy terminated
PEG2000 (Lane 4), indicating successful functionalization of the
qdot surface.
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Figure 5: Fluorescence images (top row) and bright-ﬁeld images
(bottom row) of oocytes incubated with qdot-containing com-
pounds for 10 minutes. The bright-ﬁeld images illustrate the plane
of focus of the opaque oocyte. Panels A and B show results
from a human ρ1G A B A C-expressing oocyte incubated with 34nM
muscimol-conjugated AMP-coated qdots. Panels C and D show
ah u m a nρ1G A B A C-expressing oocyte incubated with a 34nM
s o l u t i o no fu n c o n j u g a t e dA M P - c o a t e dq d o t s .P a n e l sEa n dFs h o wa
nonexpressing oocyte incubated with 34nM muscimol-conjugated
AMP-coated qdots. Adapted from Gussin et al. [65].
expressing the human ρ1 GABAC receptor, and to non-
expressing control oocytes (see Figure 5 legend). When
GABAC-expressing oocytes were incubated with a 34nM
solution of muscimol-conjugated dots for 10 minutes, a ﬂu-
orescent halo was observed at the oocyte surface membrane6 Journal of Biomedicine and Biotechnology
(panel A). The intensity of this halo exceeded that of the
surrounding extracellular medium. The ﬂuorescent image
can be compared with the corresponding bright-ﬁeld image
(panel B), which shows the position and focus of the oocyte.
By comparison with panel A, no ﬂuorescence halo was
observed upon similar incubation of a ρ1 GABAC-expressing
oocyte with AMP-coated qdots, that is, with a structure that
lacked muscimol (panel C). Halo ﬂuorescence of the oocyte
surface membrane was also absent when a nonexpressing
oocytewasincubatedwith34nMmuscimol-conjugateddots
(panel E). These results indicate that the muscimol ligand is
necessary for binding of the conjugate to the oocyte surface
membrane.
As noted in Section 2.1.4, the muscimol-conjugated
AMP-coated qdot preparation used in the oocyte imag-
ing experiments contained ∼150–200 muscimol-terminated
chains per qdot. In some preparations (not illustrated) of
these muscimol-conjugated AMP-coated qdots, the extracel-
lularmediumsurrounding theoocytesexhibited aggregation
of the ﬂuorescent particles. In developing the method of
preparation of the conjugate, we observed that if 2000
equivalents of the muscimol ligand were reacted with AMP-
coated qdots in the presence of 1500 equivalents of EDC and
NHS, aggregates formed that subsequently precipitated from
solution. It is likely that this aggregation is due to hydrogen
bonding between muscimol ligands on adjacent qdots. The
size and solubility of these aggregates likely depended on the
number of ligands conjugated to the qdots.
3.2. Imageanalysis
To quantify the extent of binding of muscimol-conjugated
AMP-coated qdots to the oocytes, we analyzed the surface
membrane and extracellular regions of a given ﬂuorescence
image [65]. Using MetaMorph software (Oﬄine Version
6.3r0; Universal Imaging Corp., Downington, Pa, USA), we
determined the intensities of pixels underlying a multiseg-
mented line that traced the arc-like border of the oocyte (15–
25 straight-line segments; 450–750 pixels), and tabulated
the resulting pixel values in relation to a 0–255 gray scale.
We similarly determined the intensities of pixels that cor-
responded with an identical multisegment line constructed
within the extracellular region of the image; tabulated
intensities for this control extracellular region were taken
as a measure of background (i.e., surround) ﬂuorescence.
For the image shown in Figure 5A, ﬂuorescence intensities
determined for the halo (henceforth termed “border”) at the
oocyte surface membrane and the surrounding extracellular
medium (background) were 67.31 ±36.79 (mean ±SD) and
22.30 ± 21.18, respectively. As reported by Gussin et al. [65],
results obtained in experiments similar in design to that
described in Figures 5A, 5B( h u m a nρ1 GABAC-expressing
oocytes; incubation with 34nM muscimol-conjugated dots)
indicated a border ﬂuorescence of 88.84 ± 64.84 and a
background ﬂuorescence of 31.60 ± 35.50 (n = 11),
respectively. Additional experiments of the same design (not
illustrated), conducted on oocytes expressing the perch ρ1B
receptor [65], yielded border and background ﬂuorescence
intensitiesof109.58±58.42and18.54±16.47(n = 4),respec-
tively. Aggregate results obtained in 4 experiments in which
GABAC-expressing oocytes were incubated with unconju-
gated AMP-coated qdots (see Figures 5C, 5D) yielded border
and background ﬂuorescence intensities of 15.79 ± 23.18
and 13.13 ± 18.17, respectively. Among 14 experiments that
involved the incubation of 34nM muscimol-conjugated dots
with nonexpressing oocytes (see Figures 5E, 5F), border and
background ﬂuorescence intensities were 15.14 ± 22.35 and
16.78±22.17,respectively,[65].Two-wayANOVAanalysisof
results obtained with the muscimol-conjugated AMP-coated
qdots showed that for both human ρ1 GABAC-expressing
and perch ρ1B GABAC-expressing oocytes, the ﬂuorescence
intensity of the border diﬀered signiﬁcantly from that of
the background. For nonexpressing oocytes incubated with
the conjugate, there was no signiﬁcant diﬀerence between
border and background values. In addition, the treatment
of GABAC-expressing oocytes with free (i.e., non-qdot-
conjugated) GABA, muscimol, or PEGylated muscimol sig-
niﬁcantly reduced binding of the muscimol-qdots conjugate
to the oocyte surface membrane (see Gussin et al. [65]f o r
further details).
4. DISCUSSION
The primary ﬁnding of the experiments involving the
incubation of muscimol-conjugated AMP-coated qdots with
GABAC-expressing oocytes is that these conjugates exhibit
speciﬁc binding at GABAC receptors. This binding depends
on the presence of muscimol in the conjugate, as (uncon-
jugated) AMP-coated qdots show no signiﬁcant binding
to oocytes expressing GABAC receptors. The approach
described here builds on our earlier work with PEGy-
lated serotonin attached to qdots in which we found that
these conjugates exhibited binding at serotonin transporters
expressed in HeLa and HEK cells. These ﬁndings indicate
thatitispossibletospeciﬁcallylabeltransporterproteinsand
ligand-gated receptors with qdots that have multiple copies
of a membrane receptor or membrane transporter ligand
attached through a PEG linker.
The presence of numerous copies of ligand in the
muscimol-qdot conjugate described here raises the pos-
sibility that these conjugates bind to multiple GABAC
receptors in a cross-linking fashion. Indeed, it is reasonable
to hypothesize that the multiplicity of the muscimol ligand,
aswellasthelengthofthePEGlinkerthattetherseachligand
to the qdot, favors such cross-linking. However, experiments
conducted to date, while clearly establishing the ability
of this conjugate to bind to cell-surface-expressed GABAC
receptors, do not address the extent to which receptor cross-
linking aﬀects this binding activity. Other investigators have
used ﬂuorescent probes to track the diﬀusion dynamics of
single receptors (single-particle tracking (SPT)), and such
an SPT approach could be useful for evaluating the cross-
linking activity of the present muscimol-qdot conjugate. For
example, Dahan et al. [50] have examined the diﬀusion
dynamics of glycine receptors in neuronal membranes
by labeling the receptor with a conjugate consisting of
a primary antireceptor antibody, biotinylated secondary
antibody, and streptavidin-coated qdots. To test the extentIan D. Tomlinson et al. 7
of receptor cross-linking by this conjugate, they investigated,
as a comparison system, an Fab fragment of the primary
antibody that had been linked to an organic ﬂuorophore
(Cy-3). Dahan et al. [50] found that the receptor dynamics
determinedwiththeqdotconjugateandtheCy-3-containing
molecule were similar, indicating that neither the presence of
the SA-qdots nor some other feature of the qdot-containing
conjugate promoted signiﬁcant receptor cross-linking. It
should be emphasized that the structure of the presently
described muscimol-qdot conjugate (see Figure 2)d i ﬀers
from the qdot-containing conjugate studied by Dahan et al.
[50] in several respects, including the presence of a small-
molecule ligand (muscimol) rather than an antibody as the
receptor-reactive moiety, a high valency (copy number) of
ligands per qdot, and a separation of each ligand from
the qdot by a long linking chain (PEG3400). In future
experiments, it may be possible to test for cross-linking by
the muscimol-qdot conjugate using an approach in which
GABAC receptor dynamics determined with the muscimol-
qdots conjugate are compared with those determined using a
structureoptimizedforSPT,forexample,aﬂuorescentprobe
attached to a single receptor [26, 27].
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